During the official launch of the presidential initiative for the early detection of cancerous tumors..
During the official launch of the presidential initiative for the early detection of cancerous tumors..
Minister of Health opens Egypt's first integrated laboratory for pathological and genetic testing
Minister of Health: the laboratory's operating capacity exceeds 1800 genetic tests and 400,000 cancer pathology tests annually
The Minister explained that the operation of the Early Detection and Treatment of Cancer Initiative began on 11 June last in 9 governorates as a first phase, namely (Alexandria – Qalyubia – Beheira – Damietta – South Sinai – Marsa Matrouh – Fayoum – Assiut – Port Said), and that the second phase, comprising 11 governorates, is scheduled to start by the end of this year, while the third and final phase will begin by the first quarter of 2024.
The Minister announced that the initiative has so far provided its services to 1.9 million beneficiaries, who filled in the initial questionnaire that determines the tumors targeted for early detection, noting that 17,507 citizens were referred for CT scans for the early detection of lung cancer, while another 89,787 were referred for the colon cancer early detection test, 62,576 were referred for the prostate tumor marker test, and 5048 women were referred for the early detection of cervical cancer.
The Minister affirmed that Egypt is witnessing a positive shift in the level of diagnostic development for cancerous tumors, in line with the global trend toward personalized medicine, noting that the initiative helps detect cancerous tumors at early stages in a target group of up to 30 million citizens of all age groups, in order to strengthen the national cancer control plan.
The Minister thanked the members of the scientific committee and the initiative's executive team for the effort and dedication they showed in planning and implementing the initiative, and also thanked the undersecretaries of the Ministry at the health directorates of the first 9 governorates in which the initiative was launched.
For her part, Dr. Nehal Nabil, Head of the Oncology Sector at “Roche”, speaking on behalf of Dr. Mohamed Sweilam and Dr. Lilian Kanaan, General Managers of Roche Pharmaceuticals and Roche Diagnostics Solutions in Egypt, said: “We are proud to cooperate with the Ministry of Health and Population in more than one presidential initiative, and today we are cooperating in one of the most important initiatives, which addresses a very important problem in health care in Egypt, and in which we and our partners are establishing the first integrated oncology laboratory in Egypt. The importance of genetic testing and integrated pathology lies in the fact that they help identify patients who can be treated with advanced targeted therapy, and they use modern technologies, which helps improve the patient journey and significantly increase the cure rate of Egyptian cancer patients.”
Dr. Ahmed Shawky, Managing Director of Sysmex Egypt and North Africa, said that in recent years Egypt has been able to build a health care infrastructure in line with the country's economic expansion and population growth, and that the health care market is expected to expand further, with growing demand for advanced testing and health care services, expressing the pride of “Sysmex” in participating in the largest project for the early screening and treatment of cancerous tumors, particularly colon cancer screening, in partnership with the Ministry of Health and Population.
For his part, Dr. Mohamed Abou El-Naga, General Manager of HVD in Egypt, the official representative of the global company “Illumina Inc”, a leader in genetic sequencing testing, said: “Our presence today at the opening of the first integrated laboratory for pathological and genetic testing is a practical culmination of our vision and an extension of the fruitful cooperation between the Ministry of Health and Population and HVD in Egypt,” noting that this cooperation confirms the state's efforts to develop the health care system and improve the quality of medical services provided to citizens in order to ensure them a decent life, within the framework of implementing the presidential initiative.
Abou El-Naga added: “The integrated oncology laboratory enhances the use of targeted therapy, thus becoming the nucleus for the detection and early diagnosis of genetic diseases in Egypt, as the new laboratory offers the latest genetic sequencing equipment, a pivotal step in providing diagnostic and health care services at the highest level.”
Dr. Mohamed Abdou, Executive Director of Commercial Partner Account Management at Illumina for genetic sequencing in the Middle East, said that the company believes in the need for the private and government sectors to join efforts to drive progress in personalized oncology, stemming from its firm belief in the importance of continuously developing the testing methods used to identify cancers as well as to determine the best treatment options.
He continued: “The current development in the health care sector, with the ability to collect the genetic and clinical information needed to determine the most effective treatment for each patient, contributes to improving outcomes and reducing side effects,” affirming that the company will continue to support cancer prevention programs in Egypt through research cooperation with experts and specialists and by providing the latest gene analysis technologies, in addition to checking for any genetic changes that may be linked to cancer in order to contribute to its treatment.